Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Capital Expenditures (2021 - 2025)

Kezar Life Sciences' Capital Expenditures history spans 5 years, with the latest figure at $8000.0 for Q1 2025.

  • For Q1 2025, Capital Expenditures changed N/A year-over-year to $8000.0; the TTM value through Sep 2025 reached $19000.0, up 101.06%, while the annual FY2024 figure was $29000.0, N/A changed from the prior year.
  • Capital Expenditures for Q1 2025 was $8000.0 at Kezar Life Sciences, down from $11000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $1.4 million in Q2 2023 and bottomed at -$1.8 million in Q4 2023.
  • The 5-year median for Capital Expenditures is $121500.0 (2022), against an average of $37571.4.
  • The largest annual shift saw Capital Expenditures tumbled 550.0% in 2022 before it soared 1185.98% in 2023.
  • A 5-year view of Capital Expenditures shows it stood at $264000.0 in 2021, then crashed by 550.0% to -$1.2 million in 2022, then tumbled by 52.27% to -$1.8 million in 2023, then soared by 100.61% to $11000.0 in 2024, then dropped by 27.27% to $8000.0 in 2025.
  • Per Business Quant, the three most recent readings for KZR's Capital Expenditures are $8000.0 (Q1 2025), $11000.0 (Q4 2024), and $18000.0 (Q3 2024).